Viking Therapeutics (VKTX) Invested Capital (2016 - 2025)
Historic Invested Capital for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $639.1 million.
- Viking Therapeutics' Invested Capital fell 2740.23% to $639.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $639.1 million, marking a year-over-year decrease of 2740.23%. This contributed to the annual value of $639.1 million for FY2025, which is 2740.23% down from last year.
- Per Viking Therapeutics' latest filing, its Invested Capital stood at $639.1 million for Q4 2025, which was down 2740.23% from $713.0 million recorded in Q3 2025.
- In the past 5 years, Viking Therapeutics' Invested Capital registered a high of $933.9 million during Q1 2024, and its lowest value of $134.1 million during Q1 2023.
- For the 5-year period, Viking Therapeutics' Invested Capital averaged around $470.0 million, with its median value being $358.3 million (2023).
- Its Invested Capital has fluctuated over the past 5 years, first crashed by 2901.45% in 2022, then soared by 59659.64% in 2024.
- Viking Therapeutics' Invested Capital (Quarter) stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then surged by 139.76% to $348.4 million in 2023, then soared by 152.65% to $880.3 million in 2024, then decreased by 27.4% to $639.1 million in 2025.
- Its Invested Capital stands at $639.1 million for Q4 2025, versus $713.0 million for Q3 2025 and $795.5 million for Q2 2025.